利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.047 秒)

    Humanized antibody specific for human 4-1BB
    1.
    发明授权
    Humanized antibody specific for human 4-1BB 失效
    对人4-1BB特异的人源化抗体

    公开(公告)号：US06458934B1

    公开(公告)日：2002-10-01

    申请号：US09438954

    申请日：1999-11-12

    申请人： Hyo Jeong Hong ,  Sung Sup Park ,  Young Jun Kang ,  Chang-Yuil Kang ,  Sung Kwan Yoon

    发明人： Hyo Jeong Hong ,  Sung Sup Park ,  Young Jun Kang ,  Chang-Yuil Kang ,  Sung Kwan Yoon

    IPC分类号： C07K1618

    CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2319/00

    摘要： The present invention is directed to humanized antibodies that specifically bind the protein 4-1BB. The antibodies can be made by grafting of the complementarity determining regions (CDR's) of mouse monoclonal antibody to human 4-1BB to the remaining portions of a human antibody and by making further amino acid replacements. In addition, a pharmaceutical composition that includes the humanized antibody can be made and can be used to treat autoimmune diseases to suppress an immune response. The humanized antibody of the invention has high affinity for human 4-1BB, and exhibits sequence similarity to human antibody. As a result, the pharmaceutical composition of the present invention can be used to treat autoimmune disease and act as an immunosuppressant in humans without much side-effect.

    摘要翻译： 本发明涉及特异性结合蛋白4-1BB的人源化抗体。 可以通过将小鼠单克隆抗体的互补决定区（CDR）与人4-1BB接枝到人抗体的其余部分并进一步进行氨基酸替换来制备抗体。 此外，可以制备包含人源化抗体的药物组合物，并且可以用于治疗自身免疫疾病以抑制免疫应答。 本发明的人源化抗体对人4-1BB具有高亲和力，与人抗体具有序列相似性。 结果，本发明的药物组合物可以用于治疗自身免疫性疾病，并且在人体中作为免疫抑制剂没有太多的副作用。

    B CELL-BASED VACCINE LOADED WITH THE LIGAND OF NATURAL KILLER T CELL AND ANTIGEN
    3.
    发明申请
    B CELL-BASED VACCINE LOADED WITH THE LIGAND OF NATURAL KILLER T CELL AND ANTIGEN 有权
    基于B细胞的疫苗与天然杀伤细胞和抗原的配体

    公开(公告)号：US20100028380A1

    公开(公告)日：2010-02-04

    申请号：US11718391

    申请日：2006-04-27

    申请人： Chang-Yuil Kang ,  Yeonseok Chung ,  Hyun-Jeong Ko ,  Yeon-Jeong Kim ,  Byung-Seok Kim ,  Sung-Youl Ko

    发明人： Chang-Yuil Kang ,  Yeonseok Chung ,  Hyun-Jeong Ko ,  Yeon-Jeong Kim ,  Byung-Seok Kim ,  Sung-Youl Ko

    IPC分类号： A61K39/12 ,  A61K39/00 ,  A61K39/02

    CPC分类号： A61K39/0011 ,  A61K39/00 ,  A61K2039/5156 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/472

    摘要： The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with α-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.

    摘要翻译： 本发明涉及一种装载有天然杀伤T细胞配体的B细胞疫苗和用于预防和治疗疾病的抗原，更具体地说，涉及一种由装载有α-半乳糖神经酰胺的B细胞介导的免疫治疗和预防性疫苗 的可以刺激天然杀伤T细胞的糖脂。 本发明的疫苗组合物可以有效地用作抗肿瘤免疫治疗剂。 B细胞与树突细胞相比容易获得，不仅诱导与常规树突状细胞基疫苗相似的细胞毒性T淋巴细胞水平的水平，而且对实体瘤和转移性肿瘤具有预防和治疗作用。

    Vaccine Composition Comprising Alpha-Galactosylceramide as an Adjuvant For Intranasal Administration
    6.
    发明申请
    Vaccine Composition Comprising Alpha-Galactosylceramide as an Adjuvant For Intranasal Administration 审中-公开
    包含α-半乳糖神经酰胺作为佐剂用于鼻内给药的疫苗组合物

    公开(公告)号：US20080317769A1

    公开(公告)日：2008-12-25

    申请号：US11995505

    申请日：2006-04-03

    申请人： Chang-Yuil Kang ,  Sung-Youl Ko

    发明人： Chang-Yuil Kang ,  Sung-Youl Ko

    IPC分类号： A61K39/00 ,  A61P43/00

    CPC分类号： A61K39/39 ,  A61K2039/543 ,  A61K2039/55511 ,  A61K2039/55572

    摘要： The present invention related to a vaccine composition comprising alpha-galactosylceramide (αGalCer) as an adjuvant for the intranasal administration. The present inventors administered αGalCer together with a tumor cell antigen or a virus antigen to the nasal cavity of a mouse and then confirmed that the αGalCer effectively induced not only humoral immunity but also cell-mediated immunity. Thus, the αGalCer can be effectively used as an adjuvant for a vaccine by the intranasal administration for the prevention and treatment of virus infection and cancer.

    摘要翻译： 本发明涉及包含作为鼻内给药佐剂的α-半乳糖神经酰胺（αGalCer）的疫苗组合物。 本发明人将αGalCer与肿瘤细胞抗原或病毒抗原一起施用于小鼠的鼻腔，然后证实αGalCer不仅有效地诱导体液免疫，而且有效地诱导细胞介导的免疫。 因此，αGalCer可以有效地用作鼻内给药用于预防和治疗病毒感染和癌症的疫苗的佐剂。

    Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen
    7.
    发明授权
    Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen 有权
    包含单核细胞或未成熟骨髓细胞（IMC）的疫苗，其装载有天然杀伤T细胞和抗原的配体

    公开(公告)号：US09518126B2

    公开(公告)日：2016-12-13

    申请号：US12279166

    申请日：2007-11-28

    申请人： Chang-Yuil Kang ,  Hyun-Jeong Ko ,  Jung-Mi Lee ,  Yeon-Jeong Kim

    发明人： Chang-Yuil Kang ,  Hyun-Jeong Ko ,  Jung-Mi Lee ,  Yeon-Jeong Kim

    IPC分类号： A61K31/164 ,  C12N5/0786 ,  A61K39/00 ,  C07K16/32

    CPC分类号： C07K16/32 ,  A61K31/164 ,  A61K39/00 ,  A61K2039/5154 ,  A61K2039/5158 ,  C12N5/0645 ,  C12N2501/999 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/472 ,  Y02A50/476

    摘要： The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with α-galactosylceramide (αGalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.

    摘要翻译： 本发明涉及包含负载天然杀伤T细胞配体的单核细胞或未成熟骨髓细胞（IMC）的免疫治疗和预防性疫苗，以及用于预防和治疗感染性疾病或癌症的抗原，更准确地说， 包含装载有α-半乳糖神经酰胺（αGalCer），一种糖脂和天然杀伤T细胞配体的单核细胞或IMC的治疗和预防性疫苗和抗原。 与树突状细胞不同，易于获得的单核细胞或未成熟骨髓细胞（IMC）不仅诱导显着水平的细胞毒性T淋巴细胞应答，而且对恶性肿瘤具有预防和治疗作用。 因此，本发明的免疫治疗和预防性疫苗可以有效地用作免疫治疗剂。

    B cell-based vaccine loaded with the ligand of natural killer T cell and antigen
    8.
    发明授权
    B cell-based vaccine loaded with the ligand of natural killer T cell and antigen 有权
    以B细胞为基础的疫苗，加载有天然杀伤T细胞和抗原的配体

    公开(公告)号：US08003093B2

    公开(公告)日：2011-08-23

    申请号：US11718391

    申请日：2006-04-27

    申请人： Chang-Yuil Kang ,  Yeonseok Chung ,  Hyun-Jeong Ko ,  Yeon-Jeong Kim ,  Byung-Seok Kim ,  Sung-Youl Ko

    发明人： Chang-Yuil Kang ,  Yeonseok Chung ,  Hyun-Jeong Ko ,  Yeon-Jeong Kim ,  Byung-Seok Kim ,  Sung-Youl Ko

    IPC分类号： A01N63/02 ,  A61K39/00 ,  A61K39/02 ,  A61K39/12

    CPC分类号： A61K39/0011 ,  A61K39/00 ,  A61K2039/5156 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/472

    摘要： The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with α-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.

    摘要翻译： 本发明涉及一种负载有天然杀伤T细胞配体的B细胞疫苗和用于预防和治疗疾病的抗原，更具体地说，涉及一种由装载有α-半乳糖神经酰胺的B细胞介导的免疫治疗和预防性疫苗 的可以刺激天然杀伤T细胞的糖脂。 本发明的疫苗组合物可以有效地用作抗肿瘤免疫治疗剂。 B细胞与树突细胞相比容易获得，不仅诱导与常规树突状细胞基疫苗相似的细胞毒性T淋巴细胞水平的水平，而且对实体瘤和转移性肿瘤具有预防和治疗作用。